Implications of low muscle mass across the continuum of care: a narrative review
doi: 10.3390/ijms21207551 241 SukritiS.TauseefM.YazbeckP.MehtaD
Among those planning to skip a dose, 51% say their physician advised against it, while 29% say their doctor said it was acceptable
However, increasing recognition of sex differences in metabolic and neuroendocrine disease suggests that such dimorphism may represent a therapeutic opportunity rather than a barrier
Comparing Semaglutide and Tirzepatide While both semaglutide and tirzepatide are effective in managing obesity and type 2 diabetes, their mechanisms of action differ slightly: Semaglutide is a GLP-1 receptor agonist that primarily works by: - Slowing gastric emptying - Reducing appetite through brain signaling - Stimulating insulin release from the pancreas - Decreasing glucagon secretion Tirzepatide, on the other hand, is a dual GIP and GLP-1 receptor agonist, often referred to as a "twincretin"[8]
Or will high costs, insurance restrictions, side effect burdens, and supply constraints limit them to a small fraction of eligible patients